Pregnant women to benefit from progesterone trial

Mater’s Fertility Assessment and Research team require pregnant women who are at risk of miscarriage to take part in a trial which aims to lower the rate of miscarriage in pregnancy.

The randomised, placebo-controlled trial—Supporting Threatened Outcomes with Progesterone—involves women in their first trimester who have a ‘threatened’ miscarriage to take daily doses of progesterone.  

Mater Fertility Service Principal Investigator Dr Luke McLindon said progesterone was necessary for maintenance of pregnancy and often these levels were lower in pregnancies that ended in miscarriage. 

“Progesterone creates a mature endometrium and a favourable immunity environment for early embryonic development,” Dr McLindon said. 

“With the exception of anticoagulants for thrombophilias, there is presently no agreed therapeutic approach which has been shown to reduce the risk of pregnancy loss in women who present with a threatened miscarriage.

“Our belief is that by supporting this early pregnancy with progesterone we may be able to improve the pregnancy outcome for many couples.” 

Women who are up to 10 weeks pregnant and who present with a threatened miscarriage, including spotting and bleeding, are suitable candidates for the trial. 

Participants will be required to self-administer pessaries containing either progesterone or placebo

every night up to 12 weeks gestation. 

“There are minimal side-effects from the pessaries and they are safe to use in pregnancy,” Dr McLindon said. 

For more information contact Mater Fertility Clinic on telephone 07 3163 8437. 

Tags:

Was this information helpful?

Personal
Was this helpful?
 Security code